LabCorp's Acquisition of Genzyme Genetics Adds to Oncology Molecular Dx Assets

Genzyme's genetics division, when combined with the Monogram Biosciences assets that it acquired last year, should help bolster LabCorp's position as a provider of personalized medicine products for cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.